Clinical and structural damage outcomes in axial spondyloarthritis patients receiving NSAIDs or advanced therapies: a description of a real-life cohort.
| Autor: | Mocritcaia A; Rheumatology Department, Hospital Clínic, Barcelona, Spain., Chacur C; Rheumatology Department, Hospital Clínic, Barcelona, Spain., Adao Abe CD; Rheumatology Department, Hospital Clínic, Barcelona, Spain., Azuaga-Piñango AB; Rheumatology Department, Hospital Clínic, Barcelona, Spain., Frade-Sosa B; Rheumatology Department, Hospital Clínic, Barcelona, Spain., Sarmiento-Monroy JC; Rheumatology Department, Hospital Clínic, Barcelona, Spain., Alascio L; Rheumatology Department, Hospital Clínic, Barcelona, Spain., Gómez-Puerta JA; Rheumatology Department, Hospital Clínic, Barcelona, Spain., Sanmartí R; Rheumatology Department, Hospital Clínic, Barcelona, Spain., Cañete JD; Rheumatology Department, Hospital Clínic, Barcelona, Spain., Ramírez J; Rheumatology Department, Hospital Clínic, Barcelona, Spain. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in medicine [Front Med (Lausanne)] 2024 Jun 20; Vol. 11, pp. 1425449. Date of Electronic Publication: 2024 Jun 20 (Print Publication: 2024). |
| DOI: | 10.3389/fmed.2024.1425449 |
| Abstrakt: | Introduction: This study aims to describe the clinical characteristics, disease activity, and structural damage in patients with axial spondyloarthritis (axSpA) who receive chronic treatment with nonsteroideal anti-inflammatory drugs (NSAIDs) or advanced therapies in a clinical setting. Methods: Cross-sectional study on axSpA patients consecutively recruited from the outpatient clinic of a tertiary hospital. We collected data on clinical and demographic characteristics, as well as treatment patterns involving NSAIDs and advanced therapies. Structural damage was assessed using mSASSS. Results: Overall, data from 193 axSpA patients (83% ankylosing spondylitis) were gathered, with a mean disease duration of 21.4 years. Of these, 85 patients (44%) were exclusively taking NSAIDs, while 108 (56%) were receiving advanced therapies, with TNF inhibitors being the predominant choice (93 out of 108, 86.1%). Among patients using NSAIDs, 64.7% followed an on-demand dosing regimen, while only 17.6% used full doses. Disease activity was low, with a mean BASDAI of 3.1 and a mean ASDAS-CRP of 1.8. In comparison to patients under chronic NSAID treatment, those taking advanced therapies were primarily male (69.4% versus 51.8%, p = 0.025) and significantly younger (mean age of 49 versus 53.9 years, p = 0.033). Additionally, patients on advanced therapies exhibited lower ASDAS-CRP ( p = 0.046), although CRP serum levels and BASDAI scores did not differ between the two groups. In the multivariable analysis, therapy (NSAID versus biological treatment) was not independently associated with ASDAS-CRP, BASDAI or mSASSS. Conclusion: This cross-sectional analysis of a real-world cohort of axSpA patients shows positive clinical and radiological outcomes for both NSAIDs and advanced therapies. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Mocritcaia, Chacur, Adao Abe, Azuaga-Piñango, Frade-Sosa, Sarmiento-Monroy, Alascio, Gómez-Puerta, Sanmartí, Cañete and Ramírez.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|